OBJECTIVE: GRIM 200 is an epidemiology survey on migraine that was performed in France in 2000, ten years after the first one (GRIM). The goal of this study was to estimate the evolution of epidemiological data since ten years, and to assess the impact of triptans on the disease management and social repercussions of migraine. METHODS: The survey was carried out by I.S.L, a national institute, on a representative sample of 10,585 subjects in France aged 15 years and older according to the quota method. There were 2 successive home interviews. Persons suffering from headache were selected during the first interview, or screening. They were then contacted for a second interview with a validated questionnaire for diagnosis of migraine. This questionnaire was the same used in 1989 with supplementary questions concerning triptans. RESULTS: We found a 8.2% prevalence of certain migraine (1-1 and 1-2 IHS) and a 17.3% prevalence of certain migraine and migraine disorder (1-7 IHS). Only 5.65% of headache sufferers (n=1486) were treated by triptans. By these 5.65% of patients using triptans, we found 4.23% of migraine sufferers, 0.2% of tension-type headache and 1.2% of chronic daily headache. We found that 2.96% of general population were chronic daily headache patients (n=152). By them, 18 patients were triptans abusers (11.8%). CONCLUSION: This study confirmed that triptans use by migraine patients is very low in France in general population. Overuse of triptans seems to be low in comparison with others drugs.